Abstract
B7-H1 was originally identified by homology analysis in comparison with B7-1 and B7-2, two molecules with important immunoregulatory functions. B7-H1, however, was broadly induced in the majority of peripheral tissues as well as hematopoietic cells. Upon binding to an as yet unidentified costimulatory receptor on primed T-cells, B7-H1 costimulates T-cell proliferation and preferentially induces interleukin 10 and interferon γ. The costimulatory function of B7-H1 may be critical for enhancing maturation and differentiation of T-cells in lymphoid organs. Conversely, by binding to programmed death 1 receptors on activated T-cells and B-cells, B7-H1 may inhibit ongoing T-cell responses in peripheral tissues by inducing apoptosis and arresting cell-cycle progression. Although a positive regulatory role of B7-H1 has been demonstrated in vitro and in various animal models, a negative regulatory role of B7-H1 has also been documented in human diseases, including cancer, rheumatoid arthritis, and human immunodeficiency virus infection. Delineation of the complex interactions between B7-H1 and its receptors as well as its interplay with other ligands is critical for understanding this new immunoregulatory system. Precise manipulation of B7-H1 and its receptors may provide unique opportunities for designing new disease treatments.
Similar content being viewed by others
References
Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity.Immunol Today. 1993;14:483–486.
Chambers CA, Allison JP. Co-stimulation in T cell responses.Curr Opin Immunol. 1997;9:396–404.
Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen.Annu Rev Immunol. 1993;11:191–212.
Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation.Annu Rev Immunol. 1996;14:233–258.
Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.Immunity. 1995;3:87–98.
Allison JP, Krummel MF. The Yin and Yang of T cell costimulation.Science. 1995;270:932–933.
Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Nat Med. 1999;5:1365–1369.
Tamura H, Dong H, Zhu G, et al. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function.Blood. 2001;97:1809–1816.
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.J Exp Med. 2000;192:1027–1034.
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.EMBO J. 1992;11:3887–3895.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.Immunity. 1999;11:141–151.
Petroff MG, Chen L, Phillips TA, Hunt JS. B7 family molecules: novel immunomodulators at the maternal-fetal interface.Placenta. 2002;23(suppl A):S95-S101.
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.Nat Immunol. 2001;2:261–268.
Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.J Exp Med. 2001;193:839–846.
Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha.Immunity. 1999;11:423–432.
Yoshinaga SK, Zhang M, Pistillo J, et al. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS.Int Immunol. 2000;12:1439–1447.
Wang S, Zhu G, Chapoval AI, et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS.Blood. 2000;96:2808–2813.
Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.Nature. 1999;397:263–266.
Mages HW, Hutloff A, Heuck C, et al. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand.Eur J Immunol. 2000;30:1040–1047.
Coyle AJ, Lehar S, Lloyd C, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses.Immunity. 2000;13:95–105.
Tafuri A, Shahinian A, Bladt F, et al. ICOS is essential for effective T-helper-cell responses.Nature. 2001;409:105–109.
Grimbacher B, Hutloff A, Schlesier M, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunode-ficiency.Nat Immunol. 2003;4:261–268.
Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.Nat Immunol. 2001;2:269–274.
Sun M, Richards S, Prasad DV, Mai XM, Rudensky A, Dong C. Characterization of mouse and human B7-H3 genes.J Immunol. 2002;168:6294–6297.
Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis.J Immunol. 2002;169:3581–3588.
Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function.Nat Immunol. 2001;2:203–209.
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med. 2002;8:793–800.
Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity.J Mol Med. 2003;81:281–287.
Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.J Immunol. 2003;170:1257–1266.
Ishida M, Iwai Y, Tanaka Y, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.Immunol Lett. 2002;84:57–62.
Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC.J Immunol. 2002;169:5538–5545.
Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.Nat Med. 2003;9:562–567.
Trabattoni D, Saresella M, Biasin M, et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression.Blood. 2003;101:2514–2520.
Nishimura H, Agata Y, Kawasaki A, et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.Int Immunol. 1996;8:773–780.
Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.Int Immunol. 1996;8:765–772.
Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.Trends Immunol. 2001;22:265–268.
Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.Int Immunol. 1998;10:1563–1572.
Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.Cell. 1992;68:855–867.
Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.Science. 2001;291:319–322.
Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.Proc Natl Acad Sci U S A. 2001;98:13866–13871.
Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction.J Exp Med. 2003;197:1083–1091.
Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes.Nat Immunol. 2002;3:999–1005.
Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy.Nat Immunol. 2001;2:293–299.
Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor.Annu Rev Immunol. 2001;19:683–765.
Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression.Immunology. 2001;103:131–136.
Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.J Exp Med. 1994;179:523–532.
Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed withCorynebacterium parvum.Cancer Res. 1994;54:5420–5423.
Stremmel C, Greenfield EA, Howard E, Freeman GJ, Kuchroo VK. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism.J Exp Med. 1999;189:919–930.
Maeda A, Yamamoto K, Yamashita K, et al. The expression of costimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia.Br J Haematol. 1998;102:1257–1262.
Pope B, Brown RD, Gibson J, Yuen E, Joshua D. B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy.Blood. 2000;96:1274–1279.
Salmon M, Gaston JS. The role of T-lymphocytes in rheumatoid arthritis.Br Med Bull. 1995;51:332–345.
Matsui T, Kurokawa M, Kobata T, et al. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases.J Immunol. 1999;162:4328–4335.
Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis.J Clin Invest. 2003;111:363–370.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tamura, H., Ogata, K., Dong, H. et al. Immunology of B7-H1 and Its Roles in Human Diseases. Int J Hematol 78, 321–328 (2003). https://doi.org/10.1007/BF02983556
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02983556